𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Androgen, estrogen and progestin binding sites in human leukemic cells

✍ Scribed by Laurence Danel; Pierre Martin; Edouard Escrich; Nicole Tubiana; Denis Fiè; Simone Saez

Publisher
John Wiley and Sons
Year
1981
Tongue
French
Weight
734 KB
Volume
27
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Sex steroid binding capacity was investigated in malignant cells from 32 patients with acute non‐lymphoblastic leukemia (25 patients with acute myeloid leukemia, 4 with subacute leukemia, 3 with chronic myeloid leukemia in blast crisis) and 30 patients with acute lymphoblastic leukemia. Specific binding of labelled steroids was characterized either by competition assay in cytosol fraction or by whole‐cell incorporation. In some cases further characterization of the receptor complex was attempted by sucrose gradient centrifugation and gel filtration column. The results show the presence of specific binding sites for dexamethasone (22/32 in non ALL and 30/30 in ALL), for estrogens (11/15 in non‐ALL and 5/12 in ALL), for progestins (8/25 in non‐ALL and 5/13 in ALL) and for androgens when RI881 was used as ligand (8/21 in non‐ALL and 5/10 in ALL patients) but only in 1/13 non‐ALL patients and no ALL patients when labelled 5α DHT was used. These results indicate that the blast cells from patients with acute leukemia contain specific proteins binding steroids with a high affinity. Our results for dexamethasone receptors are similar to those described in the literature in ALL and non‐ALL.

📜 SIMILAR VOLUMES

Type-II estrogen binding sites in a lymp
Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids
✍ Giovanni Scambia; Franco O. Ranelletti; Pierluigi Benedetti Panici; Mauro Piante 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 French ⚖ 566 KB

Type4 estrogen-binding sites (type-ll EBS) have been demonstrated in the human lymphoblastoid cell line IM-9 using a whole-cell assay with (6,7-'H) estradiol ('H-E,) as tracer. Competition analysis showed that the anti-estrogen tamoxifen and the flavonoids quercetin and rutin competed for (lH)-E, bi

Quercetin induces type-II estrogen-bindi
Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines
✍ G. Scambia; S. Mancuso; P. Benedetti Panici; R. De Vincenzo; G. Ferrandina; G. B 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 536 KB

## Abstract We show that flavonoids positively regulate type‐II estrogen‐binding site (type‐ll EBS) levels both in MCF‐7 (ER‐positive) and in MDA‐MB231 (ER‐negative) breast‐cancer cells. Type‐ll EBS were measured by a whole‐cell assay at 4°C for 2.5 hr using [^3^H]‐estradiol as tracer. In both cell

Growth-inhibitory effect of tamoxifen an
Growth-inhibitory effect of tamoxifen and quercetin and presence of type II estrogen binding sites in human laryngeal cancer cell lines and primary laryngeal tumors
✍ Gabriella Ferrandina; Giovanni Almadori; Nicola Maggiano; Paola Lanza; Cristiano 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 412 KB 👁 1 views

Quercetin and tamoxifen, in a range of concentrations between 0.01 and 5 M, exert a dose-dependent inhibition on the anchorage-dependent and anchorage-independent cell growth of Hep2 and CO-K3 laryngeal cancer cell lines. Cell cycle analysis revealed that the growth-inhibitory effect was associated